Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Clin Rheumatol

Search In Journal Title:

Abbravation: Clinical Rheumatology

Search In Journal Abbravation:

Publisher

Springer London

Search In Publisher:

DOI

10.1016/0009-2614(69)80239-3

Search In DOI:

ISSN

1434-9949

Search In ISSN:
Search In Title Of Papers:

Challenges and opportunities for diagnosis and tre

Authors: Carlos Pineda Carlo V CaballeroUribe
Publish Date: 2015/07/17
Volume: 34, Issue: 1, Pages: 5-7
PDF Link

Abstract

Latin America LA is a multicultural region with an estimate of just over 600 million inhabitants displaying great heterogeneity among their nations LA countries exhibit complex demographic characteristics because of the interaction of factors such as the different ethnic background of its population a history of colonialism and varying immigration patterns resulting in a diversified population that differs in every country within the region 1The LA region has experienced a health transition characterized by fast and complex epidemiological changes in the past decades combining increasing rates of noncommunicable diseases and injuries while keeping uncontrolled many existing endemic and emerging diseasesThe national health care systems within the LA area are heterogeneous in their organizational structure and complex in their operational configuration and in the principles guiding the public and private sector roles in the provision of health care services In LA medical attention for rheumatoid arthritis RA faces a dual challenge on one side competes with a budget designed to fight poverty lack of education an increasing number of patients and on the other hand the demographic and epidemiological transitions the insufficient number of rheumatologists and concentration of the workforce in large cities an insufficient budget for education and research and the backlog of accumulated problems characteristic of underdeveloped societies 2 In consequence RA is not yet considered a public health priority for the national health care systems Therefore explaining why only 56  of RA patients had access to full medical health coverage thus often excluding biologics only 58  had more than 7 years of education and 58  were of a low/lowmiddle socioeconomic status 3Previous efforts has been made to overcome this situation including the identification of barriers to health care 4 promoting access to a prompt diagnosis and treatment developing algorithms according these realities 5 educating patients and doctors 6 or estimating the economic impact of the disease in the region 7 and recently setting the standards to harmonize the treatment provided to RA patients in LA by developing a program focused in establish centers of excellence that would offer to RA patients a better care 8Additionally technological progress drug development and diagnostic capabilities advanced in the past two decades has resulted in major improvements in health outcomes for RA patients in developed countries but the cost of these innovations including joint prostheses access to biological medications and the lack of trained health personnel to deliver the specialized care still puts these out of the reach of people with RA in most low and middle income countries Education and training of health professionals also remains an unmet key priority 2Promote the educational activities and organize in conjunction with the national societies the Pan American Congress of Rheumatology as well as to promote national or regional meetings and encourage publication and dissemination of the scientific proceedings of meetings


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima–media in patients with systemic autoimmune diseases
  2. The virtuoso foot
  3. Responsiveness of the DASH score in surgically treated basal joint arthritis of the thumb: preliminary results
  4. RAPID3 scores and hand outcome measurements in RA patients: a preliminary study
  5. Bone mineral density in children with familial Mediterranean fever
  6. Chorea as a side effect of gabapentin (Neurontin®) in a patient with complex regional pain syndrome Type 1
  7. Risk factors in transient osteoporosis: a retrospective study on 23 cases
  8. Outcome of reactive arthritis after an extensive Finnish waterborne gastroenteritis outbreak: a 1-year prospective follow-up study
  9. Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement
  10. The autonomic nervous system in systemic sclerosis. A review
  11. Detection of anticardiolipin antibody IgG by time-resolved fluoroimmunoassay
  12. Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan
  13. Rheumatoid arthritis: should we shift the focus from “Treat to Target” to “Treat to Work?”
  14. Intercellular adhesion molecules in systemic lupus erythematosus patients with lupus nephritis
  15. Severe deficiency of 25-hydroxyvitamin D 3 (25-OH-D 3 ) is associated with high disease activity of rheumatoid arthritis
  16. The expression of death decoy receptor 3 was increased in the patients with primary Sjögren’s syndrome
  17. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)
  18. Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared
  19. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge
  20. Group visits for rheumatoid arthritis patients: a pilot study
  21. Identification of transcription regulatory relationships in rheumatoid arthritis and osteoarthritis
  22. The impact of current health-related quality of life on future health outlook in patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome)
  23. Two cases demonstrating thalidomide’s efficacy in refractory lupus nephritis
  24. Rheumatoid arthritis among Nigerians: the first 200 patients from a rheumatology clinic
  25. The challenge of profound hypoglycorrhachia: two cases of sarcoidosis and review of the literature
  26. Chronic intestinal pseudo-obstruction in patients with systemic lupus erythematosus: report of four cases
  27. Relationship of Q angle and joint hypermobility and Q angle values in different positions
  28. Osteoarthritis of the hip or knee: which coexisting disorders are disabling?
  29. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels
  30. T helper 1 type cytokines polymorphisms: association with susceptibility to Behçet’s disease
  31. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab
  32. Oxidative status in rheumatoid arthritis
  33. Impact and therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey
  34. Follicular bronchiolitis, an unusual cause of haemoptysis in giant cell arteritis
  35. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature
  36. Vitamin D and systemic lupus erythematosus: state of the art
  37. Clostridium difficile : an under-recognized cause of reactive arthritis?
  38. Prevalence of rheumatic diseases in Raramuri people in Chihuahua, Mexico: a community-based study
  39. Clinical utility of magnetic resonance angiography (MRA) in the diagnosis and treatment of Takayasu’s arteritis
  40. A systematic review of homoeopathy for the treatment of fibromyalgia
  41. Do hip OA patients referred to orthopedic surgeons by general practitioners and rheumatologists differ?
  42. The pathway of estradiol-induced apoptosis in patients with systemic lupus erythematosus
  43. Antistreptococcal Response is Exaggerated in Children with Familial Mediterranean Fever
  44. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register
  45. Beware of the biologicals—hospitals may die: the Rheumatism Foundation Hospital, Heinola, Finland (1951–2010)
  46. Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate
  47. QT dispersion in uncomplicated familial Mediterranean fever
  48. Ultrasonographic evaluation of the muscle architecture in patients with systemic lupus erythematosus
  49. Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin
  50. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis
  51. Autonomic dysfunction in psoriatic arthritis
  52. Exercise therapy for patients with diffuse idiopathic skeletal hyperostosis
  53. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients
  54. The changes in monosaccharide composition of immunoglobulin G in the course of rheumatoid arthritis
  55. Increased expression of IL - 28RA mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
  56. Contrast-enhanced power Doppler sonography of knee synovitis in rheumatoid arthritis: assessment of therapeutic response
  57. Long-term follow-up of autologous stem cell transplantation for severe paediatric systemic lupus erythematosus
  58. Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome
  59. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects
  60. Evaluation of a mail-delivered, print-format, self-management program for persons with systemic sclerosis
  61. Serum galectin-3 level in systemic sclerosis
  62. Non-rheumatoid erosive arthritis associated with type I hereditary angioedema
  63. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases
  64. Familial Mediterranean fever responds well to infliximab: single case experience
  65. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases
  66. The role of PET/CT in Cogan’s syndrome
  67. Treatment of osteoporosis in renal insufficiency
  68. STAT4 rs7574865 G/T polymorphism is associated with rheumatoid arthritis and disease activity, but not with anti-CCP antibody levels in a Mexican population

Search Result: